Thoratec Corporation  

(Public, NASDAQ:THOR)   Watch this stock  
Find more results for David Todd Harris�
39.88
-0.37 (-0.92%)
After Hours: 39.88 0.00 (0.00%)
Mar 3, 5:10PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 39.78 - 40.40
52 week 22.50 - 41.26
Open 40.28
Vol / Avg. 522,183.00/799,342.00
Mkt cap 2.16B
P/E 44.95
Div/yield     -
EPS 0.89
Shares 53.70M
Beta 0.74
Inst. own 98%
May 18, 2015
Thoratec Corporation Annual Shareholder Meeting (Estimated) Add to calendar
May 4, 2015
Q1 2015 Thoratec Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 10, 2015
Thoratec Corp at Barclays Healthcare Conference - 2:50PM EDT - Add to calendar
Mar 4, 2015
Thoratec Corp at Raymond James Institutional Investors Conference - 8:40AM EST - Add to calendar
Feb 12, 2015
Thoratec Corp at Leerink Global Healthcare Conference
Feb 10, 2015
Q4 2014 Thoratec Corp Earnings Call - Webcast
Feb 10, 2015
Q4 2014 Thoratec Corp Earnings Release
Jan 14, 2015
Thoratec Corp at JPMorgan Healthcare Conference - Q&A Session - Webcast
Jan 14, 2015
Thoratec Corp at JPMorgan Healthcare Conference
Dec 10, 2014
Thoratec Corp at Oppenheimer Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Jan '15) 2015
Net profit margin 9.25% 10.55%
Operating margin 12.32% 14.64%
EBITD margin - 18.10%
Return on average assets 6.07% 6.48%
Return on average equity 7.39% 7.76%
Employees 954 -
CDP Score - -

Address

6035 Stoneridge Dr
PLEASANTON, CA 94588
United States - Map
+1-925-8478600 (Phone)
+1-925-8478571 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Thoratec Corporation is engaged in mechanical circulatory support with a product portfolio to treat the range of clinical needs for advanced heart failure patients. The Company develops, manufactures and markets proprietary medical devices used for mechanical circulatory support (MCS) for the treatment of heart failure (HF) patients. For chronic circulatory support for HF patients, the Company�s primary product lines are its ventricular assist devices (VADs): HeartMate II Left Ventricular Assist System (HeartMate II), Thoratec Paracorporeal Ventricular Assist Device (PVAD), and Thoratec Implantable Ventricular Assist Device (IVAD). For acute circulatory support, the Company�s product lines are CentriMag Acute Circulatory System (CentriMag) and for pediatric patients PediMag/PediVAS Acute Circulatory System (PediMag/PediVAS).

Officers and directors

Neil F. Dimick CPA Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Taylor C. Harris Chief Financial Officer, Vice President
Age: 38
Bio & Compensation  - Reuters
Niamh Louise Pellegrini President - North America
Age: 48
Bio & Compensation  - Reuters
David A. Lehman Senior Vice President, General Counsel, Secretary
Age: 53
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Vasant Padmanabhan Ph.D. Senior Vice President - Technical Operations
Age: 47
Bio & Compensation  - Reuters
D. Keith Grossman President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
J. Daniel Cole Independent Director
Age: 67
Bio & Compensation  - Reuters
Steven H. Collis Independent Director
Age: 53
Bio & Compensation  - Reuters
William A. Hawkins III Independent Director
Age: 60
Bio & Compensation  - Reuters
Paul A. LaViolette Independent Director
Age: 56
Bio & Compensation  - Reuters